Literature DB >> 20628127

Bias and trials stopped early for benefit.

Susan S Ellenberg, David L DeMets, Thomas R Fleming.   

Abstract

Mesh：

Year:  2010        PMID： 20628127     DOI： 10.1001/jama.2010.933

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

1.  Monitoring in clinical trials: benefit or bias?

Authors:  Cecilia Nardini
Journal:  Theor Med Bioeth       Date:  2013-08

2.  Bioethics in Practice: Considerations for Stopping a Clinical Trial Early.

Authors:  Richard E Deichmann; Marie Krousel-Wood; Joseph Breault
Journal:  Ochsner J       Date:  2016

3.  FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

Authors:  Gideon M Blumenthal; Patricia Cortazar; Jenny J Zhang; Shenghui Tang; Rajeshwari Sridhara; Anthony Murgo; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2012-07-26

Review 4.  Protecting clinical trial participants and protecting data integrity: are we meeting the challenges?

Authors:  Susan S Ellenberg
Journal:  PLoS Med       Date:  2012-06-12       Impact factor: 11.069

5.  Analgecine, the extracts of Vaccinia-inoculated rabbit skin, effectively alleviates the chronic low back pain with little side effect - A randomized multi-center double-blind placebo-controlled phase 3 clinical trial.

Authors:  Jian Dong; Hung-Ping Tu; Wen-Yuan Ding; Yue Ding; Jin Li; Xue-Li Zhang; Cun-Yi Fan; Hai-Long Dong; Yi-Chia Wu; Sebrina Su-Jung Wang; Chen-Lung Steve Lin
Journal:  Contemp Clin Trials Commun       Date:  2015-12-19

6.  Adaptive designs in clinical trials: why use them, and how to run and report them.

Authors:  Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

7.  Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.

Authors:  Stella Erdmann; Marietta Kirchner; Heiko Götte; Meinhard Kieser
Journal:  BMC Med Res Methodol       Date:  2020-10-09       Impact factor: 4.615

8.  The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.

Authors:  Derek C Angus; Scott Berry; Roger J Lewis; Farah Al-Beidh; Yaseen Arabi; Wilma van Bentum-Puijk; Zahra Bhimani; Marc Bonten; Kristine Broglio; Frank Brunkhorst; Allen C Cheng; Jean-Daniel Chiche; Menno De Jong; Michelle Detry; Herman Goossens; Anthony Gordon; Cameron Green; Alisa M Higgins; Sebastiaan J Hullegie; Peter Kruger; Francois Lamontagne; Edward Litton; John Marshall; Anna McGlothlin; Shay McGuinness; Paul Mouncey; Srinivas Murthy; Alistair Nichol; Genevieve K O'Neill; Rachael Parke; Jane Parker; Gernot Rohde; Kathryn Rowan; Anne Turner; Paul Young; Lennie Derde; Colin McArthur; Steven A Webb
Journal:  Ann Am Thorac Soc       Date:  2020-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.